Since this is the case, singular treatment indirectly targeting MYCN via AURKA may not be a viable option for NEPC treatment; however, an in vivo neuroblastoma study has shown a synergistic inhibition of tumour growth and MYCN expression with a BRD4 inhibitor (I-BET151) and alisertib [78]. This evidence concerns the gene MYCN and neuroblastoma.